Sitemap - 2024 - The Drug Development Letter
Challenges with Reproducibility
Lu-PSMA and the need to 'educate' medical professionals about its use.
Should US Taxpayers Have Payed For The AMBASSADOR Trial? A poll.
An Educational Opportunity... ESMO2024 and the LEAP-012 trial!
What is a "Seeding Trial"? Tivozanib and the TiNivo-2 trial in renal cancer #ESMO 2024
Why Should a Top FDA Official Unilaterally Approve an Expensive Gene Therapy? The Case of Elevidys.
Response Rate Tricks in Oncology: RAS inhibitors on the spot again...
Project Orbis — harmonizing up or down?
Eli Lilly's Court Victory: Dutch Agency Must Reevaluate Abemaciclib Amid Controversy
CDK4/6 inhibitors as adjuvant therapy in early breast cancer? Uncertain benefits, guaranteed harms
Are Patient Advocacy Groups Free from Industry Influence?
THEOREMM - A Novel Framework for Cancer Registration Trials
Should the LAURA trial change our practice, and how? A PRO-CON debate!
Postrecurrence treatment in neo/adjuvant trials.
EDITOR'S PICK: Overdiagnosis and Overtreatment in Melanoma.
Special post for our French-speaking followers!
Special post-ASCO 2024 edition !
My 2 hour lecture at ASCO on Critical Appraisal
Quality of life in the adjuvant setting. A close look at the ALINA trial (alectinib).
Imatinib is still better first than asciminib. Don't be fooled.
Is the CROWN deserved? Unsure. Plus, the media coverage is in a hurry!
FDA's censoring rules doubled the PFS difference, how is this possible?
Low-dose dexamethasone in patients with newly diagnosed multiple myeloma.
CDK4/6 inhibitors in novel adjuvant ASCO guideline for breast cancer. Are patients protected enough?
De-escalation in ≥1% PD-L1 metastatic melanoma: the time has come!
Do patients survive longer because they are enrolled in trials? A new JAMA study says NO.
DESTINY-Breast06 : why I hope there won't be a standing ovation at ASCO-2024.
HOW TO DO A GREAT ONCOLOGY JOURNAL CLUB... LIVE EDITION! + Q&A
FRIDAY'S GEM: overall survival in first-line metastatic breast cancer.
What to expect from the LAURA trial presentation at ASCO-2024? (a PFS benefit? take it for granted)
How the money flows at haematology and oncology FDA workshops.
CAR T-Cells in multiple myeloma, 8 lessons for now and years to come...
Neoadjuvant immunotherapy in patients with melanoma... let's get ready for ASCO-2024 plenary !
Cisplatin shortage... has costs beyond loss-of-efficacy!
The Drug Development Letter gets a New Senior Editor
Sotorasib - KRAS G12C- A regulatory failure
The US FDA's cancer drug approval process is broken and needs audit